News Sentiment

AMRN sentiment intelligence

Amarin Corporation PLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 43 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 14.88 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-9.1% over one week, -2.4% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026

Market Reaction

Price moving ahead of tone

59/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -9.1% Price reacting lower
Trend fit Trend active -2.4% over four weeks
Fair value -1.8% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 17
Negative 12

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 6
Seeking Alpha 3
Finviz 3
JD Supra 2
The National Law Review 2
MSN 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 26
Earnings 11
Regulatory and legal 4
Guidance 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 43
Finviz Direct company coverage

AMRN - Amarin Corp ADR Options

This article provides a detailed financial overview of Amarin Corp ADR (AMRN), including its latest stock performance, key financial metrics, and insider/institutional ownership data. It presents a snapshot of the company's valuation, profitability, and stock volatility, alongsid

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 12:40
Source
Finviz
GuruFocus Direct company coverage

Amarin Corp PLC (AMRN) Stock Forecast, Price Targets and Analysts Predictions

This article provides a stock forecast, price targets, and analyst predictions for Amarin Corp PLC (AMRN). It highlights the company's market capitalization, enterprise value, and various financial ratios, offering a comprehensive overview for potential investors. The data is sou

Tone
Neutral 50/100
Event
Guidance
Published
03 Jul 2026 12:39
Source
GuruFocus
Finviz Direct company coverage

AMRN - Amarin Corp ADR Volatility & Greeks

The article provides a detailed financial snapshot of Amarin Corp ADR (AMRN), including its volatility, Greek values, performance metrics, and key financial ratios. It lists various financial data points like market cap, sales, EPS, insider ownership, and price performance over d

Tone
Neutral 50/100
Event
Earnings
Published
03 Jul 2026 12:10
Source
Finviz
Pluang Direct company coverage

Amarin highlights VASCEPA's proven role and affordability in treating severe hypertriglyceridemia amid new therapies.

Amarin Corporation has emphasized the continued importance of VASCEPA (icosapent ethyl) for treating severe hypertriglyceridemia (sHTG), despite the emergence of new injectable APOC3 therapies. The company highlights VASCEPA's strong clinical benefits, including a 33% median trig

Tone
Positive 76/100
Event
Market update
Published
02 Jul 2026 11:39
Source
Pluang
Stock Titan Direct company coverage

AMARIN (AMRN) CEO Berg exercises RSUs as ADSs, 3,197 shares withheld for tax

AMARIN (AMRN) CEO Aaron Berg reported routine equity compensation, converting 6,250 Restricted Stock Units (RSUs) into American Depositary Shares (ADSs). To cover tax liabilities from this vesting, 3,197 ADSs were withheld by the issuer at $16.35 per ADS. Following these transact

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 21:10
Source
Stock Titan
Stock Titan Direct company coverage

Amarin says VASCEPA remains a first-line option as triglyceride drugs expand

Amarin (NASDAQ: AMRN) is reaffirming VASCEPA's role as a first-line treatment for severe hypertriglyceridemia (sHTG) amidst the approval of new injectable APOC3 therapies. The company highlights VASCEPA's proven efficacy in reducing triglycerides by 33% and cardiovascular events

Tone
Positive 70/100
Event
Regulatory and legal
Published
01 Jul 2026 07:10
Source
Stock Titan
Market source Direct company coverage

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape

Amarin Corporation plc highlights the continued importance of its product, VASCEPA (icosapent ethyl), in the treatment of severe hypertriglyceridemia (sHTG) and elevated triglycerides, especially following the FDA approval of new injectable APOC3 therapies. The company emphasizes

Tone
Positive 71/100
Event
Regulatory and legal
Published
30 Jun 2026 20:42
Source
Market source
Yahoo! Finance Canada Direct company coverage

Is Amarin (AMRN) Outperforming Other Medical Stocks This Year?

Amarin (AMRN) is outperforming the Medical sector and its specific industry (Medical - Biomedical and Genetics) with a year-to-date return of 6.8% compared to the sector's 3.6% loss and the industry's 1.2% loss. The company holds a Zacks Rank #2 (Buy), driven by a significant 85.

Tone
Positive 70/100
Event
Market update
Published
12 Jun 2026 09:40
Source
Yahoo! Finance Canada
JD Supra Direct company coverage

Supreme Court Clarifies Pleading Standard for Induced Infringement in Hikma v. Amarin

The Supreme Court recently clarified the pleading standard for induced patent infringement, particularly in cases involving "skinny labels" for generic drugs. In Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., the Court unanimously held that a branded drug patent owner mus

Tone
Neutral 50/100
Event
Market update
Published
10 Jun 2026 16:38
Source
JD Supra
The National Law Review Direct company coverage

Hikma v. Amarin and a Clarified Standard for Induced Patent Infringement Under 35 U.S.C. § 271(b)

The Supreme Court recently clarified the standard for induced patent infringement under 35 U.S.C. § 271(b) in the case of Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., setting a higher bar for plaintiffs. The Court ruled that a complaint must plausibly allege that the de

Tone
Neutral 50/100
Event
Market update
Published
09 Jun 2026 22:40
Source
The National Law Review
The National Law Review Direct company coverage

Hikma v. Amarin: Supreme Court Reins in Induced Infringement Claims Against Skinny Label Generic Drugs

The U.S. Supreme Court has limited induced infringement claims against skinny label generic drugs in the case of Hikma v. Amarin. The court ruled that Amarin failed to plausibly allege that Hikma actively encouraged doctors to infringe on its CV-indication patents for VASCEPA, de

Tone
Negative 35/100
Event
Market update
Published
05 Jun 2026 18:09
Source
The National Law Review
MSN Direct company coverage

Amarin dealt blow as Supreme Court upholds 'skinny labels' for generics

The Supreme Court has upheld the use of "skinny labels" for generic drugs, a decision that deals a blow to Amarin. This ruling confirms that generic drug manufacturers can omit certain patented uses from their labels without infringing on a brand-name drug's patent. Amarin, which

Tone
Negative 14/100
Event
Market update
Published
05 Jun 2026 17:10
Source
MSN
JD Supra Direct company coverage

Supreme Court Clarifies Standard for Induced Infringement in Hikma v. Amarin | Mintz - Intellectual Property Viewpoints

The Supreme Court, in a unanimous decision, clarified the standard for induced patent infringement in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. The Court ruled that "skinny label" generic drug manufacturers do not induce infringement simply by commercially equating ge

Tone
Negative 13/100
Event
Market update
Published
05 Jun 2026 14:10
Source
JD Supra
McGuireWoods Direct company coverage

Supreme Court Unanimously Rules Against Induced Infringement Claims Based on Routine Generic Drug Marketing

The Supreme Court unanimously ruled in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. that routine generic drug marketing activities, such as skinny labels and standard therapeutic equivalence descriptions, do not automatically constitute active inducement of patent infrin

Tone
Negative 30/100
Event
Market update
Published
05 Jun 2026 09:39
Source
McGuireWoods
Finviz Direct company coverage

AMRN - Amarin Corp ADR Stock Price and Quote

This article provides a detailed stock quote and financial data for Amarin Corp ADR (AMRN), a pharmaceutical company focused on cardiovascular health. It includes various financial metrics, insider and institutional ownership, performance indicators, and a comprehensive list of a

Tone
Positive 60/100
Event
Market update
Published
02 Jun 2026 20:42
Source
Finviz
Market source Direct company coverage

How The Amarin (AMRN) Story Is Shifting With A Refined Fair Value And Outlook

Amarin (AMRN) has seen its target fair value refined from US$12.00 to US$12.50 per share due to updated analyst views on execution and long-term growth. The article details both bullish and bearish analyst arguments, highlighting factors such as stable shipment guidance, producti

Tone
Positive 63/100
Event
Regulatory and legal
Published
22 May 2026 04:10
Source
Market source
Minichart Direct company coverage

Amarin Corporation plc Files Form 8-K Detailing Company Information and Security Registration (May 2026)

Amarin Corporation plc's Annual General Meeting on May 13, 2026, saw several key proposals regarding share issuance, stock incentive plans, and corporate governance fail to pass. This outcome limits the company's ability to issue equity incentives to employees, potentially leadin

Tone
Negative 29/100
Event
Market update
Published
15 May 2026 17:09
Source
Minichart
Investing.com Direct company coverage

Amarin shareholders reject key proposals at annual meeting, limit equity grants

Amarin shareholders rejected several key proposals at their Annual General Meeting, including those related to director reelections, executive compensation advisory approval, and share issuance authorizations. As a result, the company's ability to grant equity incentives will be

Tone
Negative 34/100
Event
Regulatory and legal
Published
15 May 2026 11:09
Source
Investing.com
Stock Titan Direct company coverage

Amarin (NASDAQ: AMRN) investors curb new share issues and limit equity pay tools

Amarin Corporation plc shareholders rejected several key capital and governance proposals at their Annual General Meeting, including the authorization to issue new shares, an increase in the stock incentive plan, and the disapplication of pre-emption rights. This decision severel

Tone
Negative 19/100
Event
Market update
Published
15 May 2026 10:09
Source
Stock Titan
Stock Titan Direct company coverage

Amarin says overseas sales and cost cuts kept cash flow positive

Amarin (NASDAQ: AMRN) reported a 7% increase in Q1 2026 total net revenue to $45.1 million, driven by international sales and licensing. The company achieved positive cash flow for the second consecutive quarter and reiterated expectations for full-year 2026 positive cash flow, m

Tone
Positive 67/100
Event
Earnings
Published
04 May 2026 08:40
Source
Stock Titan
MSN Direct company coverage

Amarin's Q1 loss narrower than expected, sales increase Y/Y

Amarin (AMRN) reported a narrower-than-expected loss in Q1, with sales increasing year-over-year. The company's financial performance showed improvement, indicating positive trends in its operations.

Tone
Positive 72/100
Event
Market update
Published
03 May 2026 12:10
Source
MSN
Investing.com Canada Direct company coverage

Amarin Corp PLC (AMRN) Q1 2026 Earnings Call Highlights: Revenue Growth and Market Expansion ... By GuruFocus

Amarin Corp PLC (AMRN) reported strong Q1 2026 results, showing a second consecutive quarter of positive cash flow, a significantly narrowed operating loss, and increased U.S. market share for VASCEPA. Despite facing generic competition in the U.S., the company achieved revenue g

Tone
Positive 67/100
Event
Earnings
Published
02 May 2026 09:39
Source
Investing.com Canada
Insider Monkey Direct company coverage

Amarin Corporation plc (NASDAQ:AMRN) Q1 2026 Earnings Call Transcript

Amarin Corporation plc announced its Q1 2026 earnings, reporting a miss on EPS expectations but showcasing continued momentum in its new business model and global restructuring efforts, leading to positive cash flow for the second consecutive quarter. The company highlighted stro

Tone
Positive 59/100
Event
Earnings
Published
02 May 2026 07:09
Source
Insider Monkey